Evidence map›Paper›PMID 34893761›Full record

ReviewBritish journal of cancer2022

Raman spectroscopy: current applications in breast cancer diagnosis, challenges and future prospects.

Katie Hanna, Emma Krzoska, Abeer M Shaaban, David Muirhead, Rasha Abu-Eid, Valerie Speirs

Abstract readReview
In one paragraph

Review in British journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Relevance of light conditions for clinicalFrontiers in oncology · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Katie HannaSchool of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, AB24 2ZD, Scotland.ORCID http://orcid.org/0000-0001-8348-2399
Emma KrzoskaSchool of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, AB24 2ZD, Scotland.
Abeer M ShaabanDepartment of Cellular Pathology, Queen Elizabeth Hospital Birmingham and Cancer and Genomic Sciences, University of Birmingham, Mindelsohn Way, Edgbaston, Birmingham, B15 2GW, UK.ORCID http://orcid.org/0000-0001-5784-8705
David MuirheadSchool of Geoscience, University of Aberdeen, Aberdeen, AB24 3UE, UK.ORCID http://orcid.org/0000-0003-2065-6042
Rasha Abu-EidSchool of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, AB24 2ZD, Scotland.ORCID http://orcid.org/0000-0002-6634-0329
Valerie SpeirsSchool of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, AB24 2ZD, Scotland. valerie.speirs@abdn.ac.uk.ORCID http://orcid.org/0000-0002-0602-4666

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite significant improvements in the way breast cancer is managed and treated, it continues to persist as a leading cause of death worldwide. If detected and diagnosed early, when tumours are small and localised, there is a considerably higher chance of survival. However, current methods for detection and diagnosis lack the required sensitivity and specificity for identifying breast cancer at the asymptomatic or very early stages. Thus, there is a need to develop more rapid and reliable methods, capable of detecting disease earlier, for improved disease management and patient outcome. Raman spectroscopy is a non-destructive analytical technique that can rapidly provide highly specific information on the biochemical composition and molecular structure of samples. In cancer, it has the capacity to probe very early biochemical changes that accompany malignant transformation, even prior to the onset of morphological changes, to produce a fingerprint of disease. This review explores the application of Raman spectroscopy in breast cancer, including discussion on its capabilities in analysing both ex-vivo tissue and liquid biopsy samples, and its potential in vivo applications. The review also addresses current challenges and potential future uses of this technology in cancer research and translational clinical application.

Indexed as

Breast NeoplasmsSpectrum Analysis, RamanBiopsyFemaleHumansSensitivity and Specificity

Identifiers

PMID34893761
PMCPMC8661339

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.